Sobi receives positive CHMP opinion for TRYNGOLZA® (olezarsen) for the treatment of severe hypertriglyceridemia (sHTG)
Sobi received a positive CHMP opinion for TRYNGOLZA (olezarsen) to treat severe hypertriglyceridemia (sHTG) in the EU. The recommendation, based on Phase 3 CORE and CORE2 study results, shows a 72% reduction in triglyceride levels and an 85% reduction in acute pancreatitis events. The EC decision is expected in Q4 2026. Sobi has exclusive rights to commercialize TRYNGOLZA outside the US, excluding Canada and China.
How this was made
The 30-second read
Why it matters
The approval would make TRYNGOLZA the first RNA‑targeted therapy for severe hypertriglyceridemia in the EU, expanding the addressable patient pool.
Market read
The regulatory milestone could trigger price appreciation for both Sobi and Ionis as the drug moves toward EU launch.
What to watch
Potential competition from other triglyceride therapies and reimbursement uncertainties in EU markets.
Background
The CHMP opinion is the EU's final scientific assessment before the European Commission grants marketing authorization.
Ticker impact
Ionis Pharmaceuticals, sponsor of the Phase 3 studies, is quoted on the CHMP opinion and holds US commercialization rights.
moderate upside as investors view the EU opinion as validation of the drug.
Ionis already commercializes the drug in the US; EU approval expands market reach.
Market effects
Strengthens the lipid‑lowering biotech sector and may boost peer valuations.
Positive for European biotech stocks as regulatory pathway clears.
Adds a new RNA‑targeted therapy to the global market, potentially influencing global lipid‑management trends.
Counterpoint
If the EC delays or imposes restrictive labeling, the upside could be limited.
Key entities
- CompanySobi
Swedish biopharma holding exclusive EU rights to commercialize TRYNGOLZA.
- CompanyIonis Pharmaceuticals
US biotech that discovered and developed olezarsen, holding US commercialization rights.
- RegulatorEuropean Medicines Agency (EMA)
Agency whose CHMP issued the positive opinion.
